Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham P Taylor

Showing results (221-230 of 228) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 228 results.
The Lancet. Microbe|September 23, 2020
Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy studyMalick M Gibani, Christofer Toumazou, Mohammadreza Sohbati, et al.
BMJ (Clinical Research Ed.)|March 3, 2021
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy studyMaya Moshe, Anna Daunt, Barnaby Flower, et al.
Journal of Virological Methods|January 25, 2022
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utilityCarolina Rosadas, Maryam Khan, Eleanor Parker, et al.
Thorax|August 16, 2020
Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence surveyBarnaby Flower, Jonathan C Brown, Bryony Simmons, et al.
Science Advances|April 23, 2021
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunityAnnachiara Rosa, Valerie E Pye, Carl Graham, et al.
Medrxiv : the Preprint Server for Health Sciences|February 3, 2021
SARS-CoV-2 recruits a haem metabolite to evade antibody immunityAnnachiara Rosa, Valerie E Pye, Carl Graham, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Pageof 23

Showing results (221-230 of 228) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 228 results.
The Lancet. Microbe|September 23, 2020
Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy studyMalick M Gibani, Christofer Toumazou, Mohammadreza Sohbati, et al.
BMJ (Clinical Research Ed.)|March 3, 2021
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy studyMaya Moshe, Anna Daunt, Barnaby Flower, et al.
Journal of Virological Methods|January 25, 2022
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utilityCarolina Rosadas, Maryam Khan, Eleanor Parker, et al.
Thorax|August 16, 2020
Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence surveyBarnaby Flower, Jonathan C Brown, Bryony Simmons, et al.
Science Advances|April 23, 2021
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunityAnnachiara Rosa, Valerie E Pye, Carl Graham, et al.
Medrxiv : the Preprint Server for Health Sciences|February 3, 2021
SARS-CoV-2 recruits a haem metabolite to evade antibody immunityAnnachiara Rosa, Valerie E Pye, Carl Graham, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Pageof 23